MedTrace Logo

Aseptic Meningoencephalitis in Slovenia

NCT02328469 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2018-05-04

No results posted yet for this study

Summary

The main objective of this study is:

* to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia
* to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis
* to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with tick-borne encephalitis and Lyme neuroborreliosis

Conditions

  • Aseptic Meningitis

Interventions

DRUG

symptomatic therapy

patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline

DRUG

Ceftriaxone or Doxycycline

beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days

OTHER

questionnaire

Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

DRUG

Acyclovir

Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.

Sponsors & Collaborators

  • Slovenian Research Agency

    collaborator OTHER

  • University of Ljubljana School of Medicine, Slovenia

    collaborator OTHER

  • Harvard University

    collaborator OTHER

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Franc Strle, MD, PhD · UMC Ljubljana

  • Daša Stupica, MD, PhD · UMC Ljubljana

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328469 on ClinicalTrials.gov